StreetAlpha.app
Home › Stocks › CGON

CG Oncology, Inc. (CGON)

Healthcare
$78.94
▼ −6.89%
LAST CLOSE · NOV 17

CG Oncology develops cretostimogene, an investigational bladder cancer immunotherapy given directly into the bladder. It last closed at $78.94 on Nov 17, down 6.89% on the day. The average 12-month price target from 7 analysts is $95.71 (+21.2% from the last close), with a high of $115.00 and a low of $65.00. Analyst consensus is Strong Buy, based on the latest ratings from 7 firms (6 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 9 whale options trades in CGON, 78% of them bullish and 22% bearish. In the past 30 days there were 6 dark pool prints totaling $5.3M, the largest $1.3M.

AI Auto Pilots
Is CGON in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$6.2M
+183.6% vs a year ago
Net income
−$237.5M
−3851.1% margin
EPS (diluted)
−$2.76
Free cash flow
−$189.2M
−3068.0% margin
Valuation
Market cap
$7.1B
89.3M shares
P/E
–
No P/E while losing money
Price to sales
1143.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$28.2M
At Sep 30
Debt
$3.0M
At Sep 30
Shareholder equity
$991.0M
Shares outstanding
89.3M
At Nov 4
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $204K$204KFY2023FY2024: $1.1M$1.1MFY2024FY2025: $4.0M$4.0MFY2025

From CGON's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 6). Last 12 months adds up the four latest quarters.

Last report
Nov 6
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 7 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
7firms
6 Buy1 Hold0 Sell
Each firm's latest rating on CGON in the past 90 days
Average 12-month target
$95.71
▲ 21.2% upside

Based on 7 analysts who set a price target on CGON in the past 90 days. The average target is $95.71, with a high of $115.00 and a low of $65.00, compared with the last close of $78.94.

$51$74$97$120PAST 10 TRADING DAYS12-MONTH TARGETSHIGH $115AVG $95.71LOW $65May 26LAST CLOSE+12 MO$51$74$97$120PAST 10 DAYSTARGETSHIGH $115AVG $95.71LOW $65May 26LAST CLOSE+12 MO
Highest target$115.00
Average target$95.71
Lowest target$65.00
Latest rating changes
JP MorganMaintained
Nov 17Buy$113
Truist SecuritiesTarget raised
Nov 17Buy$85 → $100
RBC CapitalDowngrade
Nov 17Hold$97
WedbushTarget raised
Nov 17Buy$84 → $91
HC Wainwright & Co.Maintained
Nov 17Buy$115
DateFirmActionRatingPrice target
Nov 17JP MorganMaintainedBuy$113
Nov 17Truist SecuritiesTarget raisedBuy$85 → $100
Nov 17RBC CapitalDowngradeHold$97
Nov 17WedbushTarget raisedBuy$84 → $91
Nov 17HC Wainwright & Co.MaintainedBuy$115
Loading…

Technical Analysis

CGON · as of the Nov 17 close · updated after every close
Uptrend

The stock is 13% above its 20 day and 13% above its 50 day average. It is 15% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 62). The nearest support is the Pivot at $78.45, and the nearest resistance the swing high (Sep 2) at $79.23.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityHigh, 7.4%/day
Key levels
$93.9552 week high+19.0%
$83.46Pivot R1+5.7%
$79.23Swing high (Sep 2)+0.4%
$78.94Last close
$78.45Pivot−0.6%
$73.94Pivot S1−6.3%
$73.50Swing low (Aug 14)−6.9%
$71.02100 day average−10.0%
$68.3550 day average−13.4%
$68.2920 day average−13.5%
$66.96200 day average−15.2%
$37.0152 week low−53.1%
Indicators
RSI (14)61.68Strong, overbought above 70Neutral
MACD3.26Above its signal lineBullish
Stochastic66.5Middle of its rangeNeutral
ADX (14)28.2Trending up
Williams %R-45.0Oversold below −80, overbought above −20Neutral
CCI (20)119.4Oversold below −100, overbought above 100Overbought
Rate of change+23.2%Change over 10 sessionsBullish
ATR (14)$5.85Typical daily range, 7.4% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for CGON

What happened before

See how CGON did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Whale flow leans bullish7 bullish and 2 bearish whale options trades in the last 90 days. See Whale Flow

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D
Total alerts
9
Bullish
7
78%
Bearish
2
22%
Date span
Sep 17 – Nov 6
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
6
Notional
$5.3M
Largest print
$1.3M
Loading…

CGON Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲126 buying vs 103 selling
  • ▼Held by funds -0.9 pts
  • ▲Funds holding +5
  • ▲Superinvestors: 2 added, 0 cut
  • ▲Put/call 0.42 to 0.14
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding234229+2.2%
In funds' top 101110+10.0%
Held by funds104.1%105.0%−0.9 pts
New / increased39 / 8731 / 92+2.4%
Reduced / sold out69 / 3471 / 38−5.5%
Put/call ratio0.140.42−67.0%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CGON institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CGON is in one of them and how their past CGON trades turned out.

CGON in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CGON in an article yet. Here's the latest on the wider market.

About CG Oncology

CG Oncology is a clinical stage biopharmaceutical company developing cretostimogene, an investigational immunotherapy for bladder cancer. The treatment is delivered directly into the bladder and is being studied in patients with high risk and intermediate risk forms of the disease that have not grown into the muscle wall of the bladder. The company is based in Dallas, Texas, and its intended customers are patients with bladder cancer and the urology practices that treat them.

Headquarters
Dallas, TX